Patel Sushil — SEC insider filings
SEC reporting owner CIK 1860609. 27 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2021-05-05 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 23 legs across 14 filings — 237,840 shares, $4,395,619 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 49,026 shares @ $21.60 ($1,058,962) in Replimune Group, Inc., filed 2026-11-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | Chief Executive Officer, Director | 17 | — | 11 legs · 222,950 sh · $2,901,382 | 13 |
| Revolution Medicines, Inc. (RVMD) | Director | 10 | — | 12 legs · 14,890 sh · $1,494,237 | 20 |
Insider filings — Patel Sushil
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 49,026 @ $21.60 | EDGAR |
| 2026-08-12 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 39,341 @ $12.97 | EDGAR |
| 2026-07-01 | 4 | Revolution Medicines, Inc. (RVMD) | Option exercise (M): 2,955 @ $37.54 · Sale (S): 300 @ $183.17 · Sale (S): 900 @ $184.59 · Sale (S): 1,100 @ $185.90 · Sale (S): 858 @ $186.92 · Sale (S): 300 @ $187.83 · +5 more | EDGAR |
| 2026-06-23 | 4 | Revolution Medicines, Inc. (RVMD) | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 37,324 @ $5.08 | EDGAR |
| 2026-04-07 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 251,240 @ $0 · Grant/award (A): 376,860 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2025-12-04 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 10,000 @ $11.13 | EDGAR |
| 2025-06-30 | 4 | Revolution Medicines, Inc. (RVMD) | Grant/award (A): 3,142 @ $0 · Grant/award (A): 11,574 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 25,105 @ $8.06 | EDGAR |
| 2025-04-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 166,667 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 10,000 @ $12.42 | EDGAR |
| 2024-11-04 | 4 | Revolution Medicines, Inc. (RVMD) | Option exercise (M): 5,000 @ $24.84 · Sale (S): 5,000 @ $54.14 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-07-10 | 4 | Revolution Medicines, Inc. (RVMD) | Option exercise (M): 2,155 @ $16.80 · Sale (S): 2,155 @ $44 · Option exercise (M): 2,155 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4/A | Revolution Medicines, Inc. (RVMD) | Grant/award (A): 4,248 @ $0 · Grant/award (A): 15,955 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Revolution Medicines, Inc. (RVMD) | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,700 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 20,194 @ $6.47 | EDGAR |
| 2024-04-12 | 4 | Revolution Medicines, Inc. (RVMD) | Option exercise (M): 2,155 @ $16.80 · Sale (S): 2,155 @ $37 · Option exercise (M): 2,155 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 83,335 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 5,145 @ $24.11 · Sale (S): 553 @ $23.44 | EDGAR |
| 2023-06-12 | 4 | Revolution Medicines, Inc. (RVMD) | Grant/award (A): 5,200 @ $0 · Grant/award (A): 18,400 (derivative) @ $0 | EDGAR |
| 2023-05-18 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 15,575 @ $18.05 | EDGAR |
| 2023-04-04 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Revolution Medicines, Inc. (RVMD) | Grant/award (A): 10,500 @ $0 · Grant/award (A): 36,800 (derivative) @ $0 | EDGAR |
| 2022-05-18 | 4 | Replimune Group, Inc. (REPL) | Sale (S): 10,687 @ $14.59 | EDGAR |
| 2022-04-05 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 52,500 @ $0 · Grant/award (A): 78,750 (derivative) @ $0 | EDGAR |
| 2021-05-05 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 88,333 @ $0 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1860609 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs